Clal Biotechnology Valuation
| CBI Stock | 33.70 0.10 0.30% |
At this time, the firm appears to be overvalued. Clal Biotechnology shows a prevailing Real Value of 30.25 per share. The current price of the firm is 33.7. Our model approximates the value of Clal Biotechnology from analyzing the firm fundamentals such as return on equity of -0.45, and Profit Margin of (1.14) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Clal Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of Clal Biotechnology is based on 3 months time horizon. Increasing Clal Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Clal Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Clal Stock. However, Clal Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 33.7 | Real 30.25 | Hype 33.7 | Naive 32.65 |
The real value of Clal Stock, also known as its intrinsic value, is the underlying worth of Clal Biotechnology Company, which is reflected in its stock price. It is based on Clal Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Clal Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Clal Biotechnology Industries helps investors to forecast how Clal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Clal Biotechnology more accurately as focusing exclusively on Clal Biotechnology's fundamentals will not take into account other important factors: Clal Biotechnology Total Value Analysis
Clal Biotechnology Industries is currently forecasted to have takeover price of 89.12 M with market capitalization of 122.65 M, debt of 52.28 M, and cash on hands of 94.71 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Clal Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
89.12 M | 122.65 M | 52.28 M | 94.71 M |
Clal Biotechnology Investor Information
About 65.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Clal Biotechnology recorded a loss per share of 0.57. The entity last dividend was issued on the 29th of March 2021. Based on the key measurements obtained from Clal Biotechnology's financial statements, Clal Biotechnology Industries is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Clal Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clal Biotechnology has an asset utilization ratio of 17.3 percent. This suggests that the Company is making 0.17 for each dollar of assets. An increasing asset utilization means that Clal Biotechnology Industries is more efficient with each dollar of assets it utilizes for everyday operations.Clal Biotechnology Ownership Allocation
Clal Biotechnology holds a total of 156.85 Million outstanding shares. Clal Biotechnology Industries shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.58 percent of Clal Biotechnology outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Clal Biotechnology Profitability Analysis
The company reported the revenue of 76.96 M. Net Loss for the year was (89.58 M) with profit before overhead, payroll, taxes, and interest of 10.72 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Clal Biotechnology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Clal Biotechnology and how it compares across the competition.
About Clal Biotechnology Valuation
The stock valuation mechanism determines Clal Biotechnology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Clal Biotechnology. We calculate exposure to Clal Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Clal Biotechnology's related companies.Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
8 Steps to conduct Clal Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Clal Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Clal Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Clal Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Clal Biotechnology's revenue streams: Identify Clal Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Clal Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Clal Biotechnology's growth potential: Evaluate Clal Biotechnology's management, business model, and growth potential.
- Determine Clal Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Clal Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |